A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview

Table 2 The use of microRNAs to combat OC drug resistance

MicroRNA Nomenclature	function	target	Resistance against	Reference
miR-30a-5p	Inhibition of migration and invasion	SKP2, BCL9, and NOTCH1	Cisplatin	[108]
miR-34a	Inhibition of proliferation	HDAC1	Cisplatin	[109]
miR-34a-5p	Inhibition of proliferation and G1-phase cell cycle	PD-L1	Cisplatin	[110]
miR-98-5p	Promotion of drug resistance	miR-98-5p/Dicer1/miR-152	cisplatin	[111]
miR-136	Inhibition of proliferation	Notch3	Paclitaxel	[112]
miR-142-5p	Inhibition of drug resistance	XIAP, BIRC3, BCL2, BCL2L2, and MCL1	Cisplatin	[113]
miR-206	Inhibition of proliferation and metastasis	c-Met/AKT/mTOR Signaling Pathway		[70]
miR-338-3p	Inhibition of proliferation, motility, and EMT	WNT2B	Cisplatin	[114]
miR-383-5p	Tumor suppressor	TRIM27	Paclitaxel	[115]
miR-503-5p	Inhibition of tumor angiogenesis and growth	CD97-Mediated JAK2/STAT3 Pathway	Paclitaxel	[116]
miR-509-3p	Enhance drug sensitivity	GOLPH3 and WLS	Platinum	[117]
miR-708	Inhibition of metastasis	IGF2BP1/Akt	Cisplatin	[118]
miR-744-5p	Promotion of cell apoptosis	NFIX and HNRNPC	Carboplatin	[119]
miR-1246	Promotion of tumor growth	Cav1/p-gp/M2-type macrophage axis	Paclitaxel	[120]
miR-1307	It affects cell cycle dynamics	CIC	Paclitaxel	[94]

ISSN: 1757-2215